PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Multiple Dose Study To Determine Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Healthy Adult Subjects
- First Posted Date
- 2009-08-11
- Last Posted Date
- 2010-01-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT00956956
- Locations
- 🇸🇬
Pfizer Investigational Site, Singapore, Singapore
Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
- Conditions
- Alzheimer Disease
- Interventions
- Biological: ACC-001(30µg) + QS21Biological: ACC-001(3µg) + QS21Biological: ACC-001(10µg) + QS21
- First Posted Date
- 2009-08-10
- Last Posted Date
- 2021-03-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 160
- Registration Number
- NCT00955409
- Locations
- 🇫🇷
CMRR Bordeaux CHU Pellegrin, Bordeaux Cedex, France
🇫🇷Hopital Roger Salengro, Lille, France
🇫🇷Hôpital Roger Salengro, Lille, France
Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients
- First Posted Date
- 2009-08-06
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 38
- Registration Number
- NCT00952380
- Locations
- 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸MedStar Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸Nemours Children's Clinic, Jacksonville, Florida, United States
A Study Of PF-04449913 In Select Hematologic Malignancies
- First Posted Date
- 2009-08-06
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 47
- Registration Number
- NCT00953758
- Locations
- 🇺🇸
UCSD Medical Center - La Jolla, La Jolla, California, United States
🇺🇸Moores UCSD Cancer Center, La Jolla, California, United States
🇺🇸UCSD Medical Center - Hillcrest, San Diego, California, United States
Study Evaluating the Effect of Desvenlafaxine on the Pharmacokinetics of Midazolam
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2009-08-06
- Last Posted Date
- 2011-08-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 28
- Registration Number
- NCT00952653
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Study of Safety And Efficacy Of ReFacto AF In Previously Untreated Hemophilia A Patients In The Usual Care Setting
- Conditions
- Hemophilia A
- Interventions
- Procedure: Laboratory Tests
- First Posted Date
- 2009-07-31
- Last Posted Date
- 2019-07-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 23
- Registration Number
- NCT00950170
- Locations
- 🇫🇷
CHU de Nantes, Nantes, France
🇩🇪Medizinische Hochschule, Hannover, Hannover, Niedersachsen, Germany
🇩🇪Klinikum Bremen-Mitte gGmbH, Professor Hess Kinderklinik, Bremen, Germany
Study Evaluating The Safety And Tolerability Of Administration Of Single Oral Doses Of SAM-760 To Healthy Subjects
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-07-29
- Last Posted Date
- 2013-02-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 124
- Registration Number
- NCT00948662
- Locations
- 🇫🇷
Pfizer Investigational Site, Rueil Malmaison, France
A Multiple Dose Study of PF-04360365 In Patients With Mild to Moderate Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Interventions
- Biological: PF-04360365 10 mg/kgBiological: PF-04360365 7.5 mg/kgDrug: placebo
- First Posted Date
- 2009-07-24
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT00945672
- Locations
- 🇸🇪
Sahlgrenska Sjukhuset, CTC, Göteborg, Sweden
🇸🇪Malmo Sjukhus, Neuropsykiatriska Kliniken, Malmo, Sweden
🇸🇪Sahlgrenska Universitetssjukhuset, Minnesmottagningen, Molndal, Sweden
Observational Non-Interventional Study Of Febrile Neutropenia Patients To Evaluate Antibacterial Therapeutical Options
- Conditions
- Febrile Neutropenia
- Interventions
- Drug: Antibacterial agent for the treatment of febrile neutropenia
- First Posted Date
- 2009-07-24
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 264
- Registration Number
- NCT00945555
- Locations
- 🇹🇷
Pfizer Investigational Site, Kocaeli, Turkey
Efficacy and Safety Study of Binodenoson in Assessing Cardiac Ischemia
- First Posted Date
- 2009-07-23
- Last Posted Date
- 2012-06-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 419
- Registration Number
- NCT00944294